34 results about "Cholestasis" patented technology

Described are methods for treating alpha-1 antitrypsin deficiency (AATD) in a human patient in need of treatment, using pharmaceutical compositions that include AAT RNAi agents. The pharmaceutical compositions disclosed herein that include AAT RNAi agents, when administered to a human patient in need thereof, treat liver diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, increased risk of hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, fulminant hepatic failure, and other liver-related diseases.

The present application provides a compound of formula (I), or an optical isomer thereof, a pharmaceutically acceptable salt, a solvated form, or a prodrug. The compound may modulate NTCP function for the prevention and / or treatment of HBV / HDV and hepatitis virus-related diseases, bile acid-related cholestasis disorders, metabolic disorders, and / or liver diseases. Additionally, the present application relates to a pharmaceutical composition comprising such a compound and a method for modulating NTCP.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation and / or fibrosis in the liver, e.g., metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), primary biliary cholangitis, primary sclerosing cholangitis, alcoholic cirrhosis, hepatitis cirrhosis, cholestasis, autoimmune hepatitis, viral hepatitis B, viral hepatitis C, hemochromatosis, Wilson's disease, or alcoholic steatohepatitis, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

The application discloses application of AML-12 exosomes in preparation of medicines for treating cholestatic liver injury, relates to the technical field of biological medicine, and discloses application of AML-12 cell-derived exosomes in preparation of medicines for preventing and treating ANIT-induced cholestatic liver injury; the treatment is manifested as reduction of alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase levels in serum. The application proves that the AML-12 cell-derived exosomes have a significant treatment effect on ANIT-induced cholestatic liver injury, successfully opens up the application of the biological preparation in a brand-new disease field, and fills the blank of the prior art; through in-vivo experiments, it is proved that AML-12 exosome treatment can significantly reduce liver cell injury markers and alkaline phosphatase, a key index of cholestasis, in serum of ANIT model mice, and improve pathological injury of liver tissue, thereby constituting a complete curative effect evidence chain from function to morphology.

The invention relates to the technical field of probiotics, and discloses a probiotic preparation for improving abnormal bile diseases of newborns. According to the probiotic preparation provided by the invention, lactobacillus fermentum CECT5716, bifidobacterium breve M-16V and bifidobacterium longum subsp. Longum BB536 in the list of strains for infants are selected as a product formula, and the probiotic preparation can be used for effectively improving abnormal bile diseases of newborns, including jaundice, hyperbilirubinemia and cholestasis, and can be used for preventing and treating the abnormal bile diseases of the newborns, such as jaundice, hyperbilirubinemia and cholestasis. The problems that in the prior art, safety is insufficient, pertinence is insufficient, and clinical requirements of complex illness conditions cannot be met are effectively solved.

The invention discloses an application of an RNAm6A modification level of PTGER4 in preparation of an ICP (inductively coupled plasma) auxiliary diagnosis kit. The RNA m6A modification level of the PTGER4 in placenta tissue and whole blood of an ICP patient is remarkably reduced, and the AUC modified by the RNA m6A of the PTGER4 in the whole blood is 0.844, so that the RNA m6A modification of the PTGER4 is a biomarker highly related to ICP attack, and a laboratory support can be provided for screening, diagnosis and treatment of ICP.

The invention provides a pharmaceutical composition for treating cholestatic liver injury, and the pharmaceutical composition contains an effective amount of Ferulic acid and Wogonin. The application creatively focuses on two key links in the cholestatic liver injury process, namely (1) bile acid excretion and (2) intestinal mucous barrier protection, a synergistic component of Ferulic acid and wogonin is provided, and the optimal ratio of Ferulic acid and wogonin is verified through an experimental system. Experiments prove that the cholestatic liver injury can be effectively improved by combined application of the Ferric acid and the Wogonin which are derived from traditional Chinese medicines; in addition, the effect of the medicine composition is obviously superior to the effect of independently using the Ferric acid or the Wogonin. Wide application prospects are realized.

The invention discloses a cholestasis index-based liver cancer risk prediction model construction method, which comprises the following steps: collecting chronic HBV infected person data containing 16 parameters, carrying out desensitization, carrying out stratified random sampling to divide a data set, and carrying out two-stage screening to obtain HBsAg, ALT, ALP, GGT, PLT and AFP core features; after Min-Max Scaling processing, L1 regularization logistic regression is combined with grid search and 5-fold cross validation to construct the model, and the model constructed by the method is obviously superior to a traditional CU-HCC model and a REACH-B model, especially has higher recognition capability for early HBV-PLC, and can effectively reduce the missed diagnosis rate.

Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg / kg / day.

This invention discloses a veterinary drug composition containing Bupleurum chinense extract, its preparation method, and its application, belonging to the technical field of veterinary traditional Chinese medicine preparations. The composition consists of active ingredients (only saikosaponins a and d, in a mass ratio of 0.8–1.2:1, accounting for 5%–50% of the total content) and excipients (one or more of microcrystalline cellulose, magnesium stearate, and starch). The dosage form is tablets, granules, or powder, with each unit dose containing 5–20 mg of the total mass of both. In preparation, dried Bupleurum chinense roots are pulverized and enzymatically hydrolyzed with a 1:1 complex enzyme, ultrasonically extracted with an ethanol-sodium citrate mixture, purified with AB-8 macroporous resin, and freeze-dried to obtain saikosaponin powder. This powder is then mixed with the excipients and granulated, tableted, or packaged into the corresponding dosage form. This composition shows significant efficacy against fatty liver in chickens, hepatitis in pigs, and cholestasis in ducks, exhibiting stability, high purity, and high efficiency, providing a safe new option for the treatment of liver and gallbladder diseases in livestock and poultry.

The invention relates to inhibitors of the PKC signaling pathway for use in the treatment of septic cholestasis, wherein the inhibitors are targeted into the liver by a selective nanostructured delivery system, wherein the selective nanostructured delivery system comprises at least one polymethine dye and at least one polymer and / or at least one lipid and / or at least one virus-like particle, wherein the at least one polymethine dye is a symmetrical or asymmetrical polymethine.

The present invention relates to a method of prevention, delay of progression or treatment of cholestasis and / or fibrosis associated with cholestasis.

The present disclosure relates to compounds of the general formula (I):wherein R1, R2, R3, R4, R5, R6, and R7 may be chosen from different substituents; n is 0, 1, or 2; and X is a hydroxymethyl or a carboxylic acid or a derivative thereof, such as a carboxylate, such as a carboxylic ester, a glyceride, an anhydride, a phospholipid, a carboxamide, a phospholipid, or a prodrug thereof; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to metabolic diseases and liver diseases, such as non-alcoholic fatty liver disease and cholestasis diseases.

The invention discloses application of a gold nanocluster in preparation of a medicine for treating sepsis liver injury. Animal and cell experiments prove that the gold nanocluster has a remarkable treatment effect on sepsis liver injury (SLI), and the levels of inflammatory factors in serum of model animals and aspartate aminotransferase serving as a liver injury marker can be reduced; in an in-vitro model, the cluster compound can relieve hepatocyte mitochondrial dysfunction caused by cholestasis and bile acid metabolism disorder and promote cell survival, so that the effect of protecting hepatocytes is achieved.

The invention discloses a method for detecting metabolite containing phosphate radicals, which is characterized in that a mass spectrum label with stable and characteristic chlorine isotope distribution is introduced through a chlorination reagent derivatization strategy, so that a derivatization product can be subjected to rapid and high-specificity preliminary identification based on primary mass spectrum data. By combining with an automatic data mining program specially developed for this purpose, high-throughput and accurate screening and locking of potential phosphate radical-containing metabolites from massive and complex non-targeted metabonomics original data are realized, and the data analysis efficiency and reliability are greatly improved. The method is successfully applied to analysis of actual biological samples such as cholestasis disease models, efficient identification and accurate quantification of various key metabolites such as nucleotide and sugar phosphoric acid are achieved, disturbance of related metabolic pathways is disclosed, and a powerful innovative analysis tool is provided for disease mechanism research and biomarker discovery.

The invention discloses shRNA (short hairpin ribonucleic acid) capable of specifically inhibiting circTNK2-Mus expression and application of the shRNA. The nucleotide sequence of the shRNA is shown as SEQ ID NO. 5. The invention also provides an oligonucleotide sequence (as shown in SEQ ID NO.3-4) for coding the shRNA, a recombinant LV3 lentivirus plasmid containing the sequence, a recombinant lentivirus packaged by the recombinant LV3 lentivirus plasmid, a pharmaceutical composition containing the virus and application of the recombinant lentivirus. Experiments prove that in a cholestasis-induced hepatic fibrosis animal model, the expression of circTNK2-Mus in liver tissues can be efficiently and specifically knocked down by performing caudal vein injection on the recombinant lentivirus, the pathological indexes of fibrosis are remarkably improved, and the occurrence and development of hepatic fibrosis are effectively prevented. The invention provides a brand-new circRNA target spot and a gene therapy candidate drug with great potential for hepatic fibrosis.

The invention provides a medicine beneficial to liver cell proliferation and application. The rifampicin in the medicine has a protective effect on CCl4-induced acute liver injury of mice and bile duct ligation BDL-induced cholestatic liver injury, and can improve liver inflammation infiltration, promote liver cell proliferation and effectively drive liver repair. Besides, under the liver steady-state condition, rifampicin administration can induce liver cell proliferation, the liver / body weight ratio is remarkably increased, and liver cell proliferation under the basic state can be promoted. Therefore, rifampicin plays a key role in promoting liver regeneration in maintaining the physiological state of the liver and repairing liver injury, and is a potential drug for promoting liver regeneration.

Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg / kg / day.

The invention discloses an isoindoline-1-ketone-containing compound and a pharmaceutical composition and application thereof, the structure of the compound is shown as a formula IA or IB, the compound has good inhibitory activity on MAGL, the optimal inhibition rate on the micromolar concentration level reaches 90% or above, the inhibitory activity IC50 value reaches the nanomolar concentration level, and the compound has good application prospects. The compound can be applied to preparation of drugs for preventing and / or treating diseases related to MAGL. Comprise depression, schizophrenia, bi-directional disorder, dyskinesia, traumatic brain injury, neuroinflammation, Parkinson's disease, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, anxiety disorder, pain, metabolic disorder, alcoholic fatty liver disease, non-alcoholic fatty liver disease, hepatic fibrosis, cholestasis, nephropathy and the like.

The present invention provides novel azabicycle derivative compounds, their hydrates, their solvates, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions for the prevention or treatment of autotaxin-related diseases containing them as active ingredients. The azabicycle derivative compounds according to the present invention exhibit excellent inhibitory activity against autotaxin and can be usefully used for the treatment and prevention of autotaxin inhibition-related diseases, including fibrous diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, metabolic diseases, cancer and cancer metastasis, ocular diseases, cholestatic and other forms of chronic pruritus, and acute or chronic organ transplant rejection.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to biphenyl monoacyl compounds or pharmaceutically acceptable salts and application thereof. According to the biphenyl monoacyl compound provided by the invention, the expression of PXR downstream key protein is up-regulated by activating a PXR receptor, and the biphenyl monoacyl compound shows a good treatment effect on liver and other metabolic system diseases. The biphenyl monoacyl compound has a good effect in the aspects of promoting liver regeneration, resisting cholestasis and the like, and has a good development prospect.

Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg / kg / day.

The invention relates to the technical field of medicines, in particular to application of uric acid in preparation of a medicine for treating liver injury and a medicine for inhibiting platelets during liver injury. The invention relates to an application of uric acid in the aspects of treating liver injury and inhibiting platelet activation, which indicates that uric acid (especially exogenous uric acid) can be used for preparing the medicines for treating liver injury and platelet activation, and provides technical enlightenment for preparing the medicines for treating liver injury and liver cirrhosis hypercoagulable state. The invention discloses that exogenous uric acid has a treatment effect on acute liver injury induced by thioacetamide (TAA). The exogenous uric acid has a treatment effect on chronic liver injury caused by cholestasis. The mechanism is related to reduction of oxidative stress and inflammatory response and further reduction of cell senescence. The condition of a liver cirrhosis patient is related to the platelet activation state, exogenous uric acid inhibits TAA and platelet activation in a common bile duct ligation (BDL) rat model, and it is prompted that the liver disease and the liver cirrhosis hypercoagulable state can be treated.

The invention discloses an application of marine-derived alkaloid in preparation of an anti-cholestasis medicine, and belongs to the field of natural medicines. The invention discloses an application of indolediketopiperazine alkaloid 12R, 13S-Dihydroxyfumitorgin C (DHFC) or a pharmaceutically acceptable salt of the indolediketopiperazine alkaloid in preparation of an agonist of a peroxisome proliferator-activated receptor delta (PPAR delta), and an application of the indolediketopiperazine alkaloid 12R, 13S-Dihydroxyfumitorgin C (DHFC) or the pharmaceutically acceptable salt of the indolediketopiperazine alkaloid in preparation of an anti-cholestasis medicine, and the indolediketopiperazine alkaloid 12R, 13S-Dihydroxyfumitorgin C (DHFC) or the pharmaceutically acceptable salt of the indolediketopiperazine alkaloid has a protective effect on cholestasis by activating the PPAR delta. DHFC is in high-affinity binding with an LBD region of PPAR delta, the transcriptional level of downstream genes of PPAR delta is increased, the affinity KD of DHFC to PPAR delta protein is 153nM, and the DHFC plays a synergistic treatment role in multiple links of improving bile acid homeostasis, inhibiting inflammation, relieving liver fibrosis and the like. The invention provides a new lead compound for the development of anti-cholestasis drugs, and has important significance for the development of Chinese marine-derived drugs. Formula (I)

The present disclosure relates to compounds of the general formula (I):wherein R1, R2, R3, R4, R5, R6, and R7 may be chosen from different substituents; n is 0, 1, or 2; and X is a hydroxymethyl or a carboxylic acid or a derivative thereof, such as a carboxylate, such as a carboxylic ester, a glyceride, an anhydride, a phospholipid, a carboxamide, a phospholipid, or a prodrug thereof; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to metabolic diseases and liver diseases, such as non-alcoholic fatty liver disease and cholestasis diseases.

Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg / kg / day.

The invention discloses a method for increasing the yield of bezoar through specific forage combination feeding. According to the method, through scientific treatment and directional feeding of the ox gall powder residues, appropriate physiological conditions are created for bezoar formation. Active ingredients in the treated residues are more easily absorbed by cattle, the gallbladder contraction rhythm is mildly adjusted, cholestasis is induced, and cholesterol is crystallized and separated out, which is the core mechanism of calculus bovis generation; meanwhile, due to the interval feeding rhythm, continuous stimulation is guaranteed, excessive burden cannot be caused to the hepatobiliary system of the cattle, the calculus bovis can be gradually formed in a stable physiological environment, the yield of the calculus bovis is increased from the source, and the double advantages of resource recycling and breeding health guarantee are achieved. Originally possibly discarded ox gall powder residues are converted into effective raw materials after being treated, the breeding cost is reduced, meanwhile, waste discharge is reduced, and the method is suitable for practical application of farmers.

The invention discloses an application of taurodeoxycholic acid in preparation of a medicine for recovering damaged hematopoietic stem cells, taurodeoxycholic acid TDCA is formed by combining deoxycholic acid Deoxycholic acid, DCA and taurine, belongs to secondary bile acid, contains two hydroxyls 3 alpha and 12 alpha, and is relatively high in hydrophobicity. The TDCA can promote lipid absorption and help to emulsify fat and fat-soluble vitamins. The TDCA is mainly used for anti-inflammation and liver protection, can relieve liver inflammation and fibrosis such as non-alcoholic fatty liver disease and cholestasis through an FXR pathway and can be potentially used for treating inflammatory bowel disease IBD, and it is found that the TDCA can recover the number and functions of hematopoietic cells of mice with hematopoietic damage caused by long-term drinking of high-temperature water besides the functions.

The present invention belongs to the technical field of biomedicine. Provided are an siRNA for inhibiting the CIDEB gene expression, and a modifier and the use thereof. The double-stranded RNA molecule is any one of 196 siRNAs. The siRNA comprises a sense strand and an antisense strand that at least partially form a double-stranded region, wherein the sense strand comprises a nucleic acid sequence selected from any one of the odd-numbered sequences from sequences 1-392. The provided siRNA can efficiently degrade CIDEB mRNA and significantly reduce the level of the CIDEB protein. The siRNA can be used in the preparation of a new drug for treating NAFLD / NASH, including, but not limited to, fatty liver, NAFLD, NASH, and intrahepatic cholestasis.